Actively Recruiting
Use of 18F-Fluciclovine PET to Identify Tumors in Patients With Brain Metastases Receiving Immunotherapy
Led by University of Wisconsin, Madison · Updated on 2026-02-03
30
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
Sponsors
U
University of Wisconsin, Madison
Lead Sponsor
B
Blue Earth Diagnostics
Collaborating Sponsor
AI-Summary
What this Trial Is About
Researchers are evaluating new imaging techniques to better detect tumors in people with brain metastasis. This study focuses on comparing positron emission tomography (PET) combined with magnetic resonance imaging (MRI) against other imaging methods to determine if these newer techniques can more accurately identify cancerous tissue. Improved imaging is important to help locate tumors and guide future cancer treatments. Participants will undergo a single PET/MRI scan using a radiotracer called F-Fluciclovine, followed by a separate MRI scan with a tracer. These imaging methods are performed on the same machine that creates detailed pictures using magnets and radio waves. The PET and MRI scans assess protein levels in tumor tissue, with higher protein levels suggesting tumor presence rather than normal brain tissue. During the study visit, which lasts about three hours, participants will be asked to lie still for 30 to 60 minutes during imaging. Researchers will measure amino acid uptake into tumor tissue to compare imaging results. Patients must be able to complete the scans without requiring intravenous sedation, and medication use for mild anxiety is allowed under specific conditions. All scans and procedures are conducted to monitor tumor presence and treatment changes safely.
CONDITIONS
Brief Title
18F-FLUC PET/MR in Patients With Brain Mets
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years or older
- Able and willing to provide informed consent
- Diagnosed with brain metastasis with at least one visible tumor lesion on brain MRI
- Received radiation therapy within the past 2 years
- Currently or recently (within 6 months) treated with systemic therapy such as immunotherapy, targeted therapy, or chemotherapy
- Recent MRI suggests possible tumor recurrence versus treatment effects
- Able to lie still for 30 to 60 minutes during imaging
- Willing and able to undergo PET/MRI or PET/CT imaging
- If using oral anxiety medication for imaging, must have own prescription, consent prior to use, and come with a driver
You will not qualify if you...
- Unable or unwilling to provide informed consent
- Pregnant
- Contraindications to PET/MR or PET/CT imaging
- Known allergy to 18F-Fluciclovine or any of its components
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 3 hours
Participants undergo PET and MRI imaging using the F-Fluciclovine radiotracer to identify tumor presence and assess amino acid uptake into tumor tissue.
1 imaging visit (in-person)
Trial Site Locations
Total: 1 location
1
University of Wisconsin
Madison, Wisconsin, United States, 53705
Actively Recruiting
Research Team
R
Radiology Studies
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
DIAGNOSTIC
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here